Skip to content

Exagen Inc. XGN Debt-to-assets

Debt-to-assets at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
0.4×0.0×
Quest Diagnostics logo
Quest DiagnosticsDGX
0.4×0.0×
Vor Biopharma logo
Vor BiopharmaVOR
-0.3×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
0.0×
CareDx logo
CareDxCDNA
0.1×0.0×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
0.1×0.0×

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Calculated from Exagen Inc.’s reported figures.

Based on the most recent quarter.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s debt-to-assets?
Exagen Inc. (XGN) reported debt-to-assets of 0.5× in Q1 2026.
How has Exagen Inc.'s debt-to-assets changed year-over-year?
Exagen Inc.'s debt-to-assets decreased by 10.2% year-over-year, from 0.6× to 0.5×.
What is the long-term trend for Exagen Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), Exagen Inc.'s debt-to-assets has grown at a 5.1% compound annual growth rate (CAGR), from 0.4× to 0.5×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.